1/ In #JoCI/#Springer, @xsolanich & team report #autoAbs neutralizing high concentrations of #type1IFN in 10% of patients with critical #COVID19 pneumonia in their hospital (link.springer.com/article/10.100…).
2/ After Amsterdam (link.springer.com/article/10.100…), Lyon (onlinelibrary.wiley.com/doi/10.1002/ct…), New Haven (nature.com/articles/s4158… ), San Francisco (science.org/doi/10.1126/sc…; link.springer.com/article/10.100…), Boston(sciencedirect.com/science/articl…)…
3/ Bogota (sciencedirect.com/science/articl…) and Madrid (link.springer.com/article/10.100…), the contribution of pre-existing #autoAbs neutralizing high concentrations of #type1IFN is now replicated in Barcelona (science.sciencemag.org/content/370/65…).
4/ Note that the Journal of Clinical Immunology, the international journal in the field of inborn errors of immunity, has been at the forefront of research on #COVID19 and #autoAbs to #type1IFN. Guess why 😊
5/ The proportion of patients with critical C-19 due to pre-existing #autoAbs to #type1IFN would be probably even higher if lower, more physiological concentrations of #type1IFN were considered (science.org/doi/10.1126/sc…).
6/ Congratulations to co-authors @xsolanich, @JRosain, @Philippot, @guillerascu, @ArnauAntoliGil and other not yet on Twitter.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
